New opportunities in telemedicine
29 July 2020
Bottom line:
Regulatory and reimbursement changes could pave the way for sustained growth. Telemedicine companies relying on subscription models are better placed to profit from the unexpected acceleration fueled by the pandemic.
A new wave of investment opportunities is reaching the public market. Innovative business models are leading to the evolution of primary care. We already have exposure to the sector and keep a close eye on possible new opportunities.
Telemedicine To The Forefront
Telemedicine technology ripe for broader adoption
Telemedicine requires basic technology that is now easily available for both patients and physicians, allowing for more convenient consultation services with shorter waiting times and easier access to specialist doctors.
- Technical requirements include a secure access, sufficient broadband internet to transmit audio and video data, a video platform, the interface between the healthcare providers and patients, and a software installed on the video platform.
Covid-19 pandemic a blessing in disguise
Lockdown enforcement resulted in a surge of remote medical visits. As patients were forced to adopt telemedicine solutions, they also experienced firsthand the benefits and advantages.
- In-person visits imploded by almost 60% at the end of Q1.
- Telemedicine providers have all seen significant spikes in both subscriptions and visit-fee-only volumes.
Regulators giving in to better reimbursements
Reimbursement measures extended to telemedicine during the emergency situation are likely to remain for longer and appear as the first cracks in the dam.
- Better reimbursement rates are key to drive adoption.
- Regulators are already issuing guidelines that look to extend better reimbursement conditions for telemedicine.
Telemedicine Technology Unwrapped
Broadly available technology
Telemedicine's basic requirements include secure access to broadband internet, a video platform acting as the interface between the healthcare providers and the patients, and a dedicated software.
- Video platforms are usually home computers or app-enabled smartphones.
- Telemedicine software may allow providers to import new patient’s data into Electronic Health Records (EHR).
Peripherals
Today's technology incorporates data from peripheral devices, such as remote patient monitoring (RPM) devices, to collect and transmit health information to the physician.
- Digital stethoscopes transmit heart and lung sounds to remote providers.
- High definition videocameras, called dermascopes, allow for detailed visualization of skin problems, while otoscope cameras send clear pictures of the nose, throat and ear.
Patient privacy
Telemedicine services must guarantee privacy for patients’ personal health data. Today, housing digital data on third-party remote servers may be more secure than locale servers.
- In the U.S. patient data protection requires telemedicine providers to be compliant with Health Insurance Portability and Accountability Act (HIPAA).
- Applications such as Skype or WhatsApp are not HIPAA-compliant.
The Pandemic Has Pushed Telemedicine Into The Future
COVID-19: the unexpected catalyst
COVID pandemic forced healthcare institutions and regulatory bodies to adopt telemedicine as an effective way to limit the viral spread.
- The American Medical Association (AMA) released telemedicine specific guidelines.
- The U.S. government expanded reimbursement coverage and lifted regulatory restrictions.
Unprecedented adoption in the wake of coronavirus
As the COVID-19 spread around the world, The Centers for Medicare & Medicaid Services (CMS) temporarily expanded its reimbursement coverage for telemedicine.
CMS approved more than 80 new telemedicine services, waived geographic restrictions and included telephone consultations.
- CMS is paying telemedicine services at the same rate of in-person visits.
Is the use of telemedicine already fading?
During the COVID, the number of in-person visits dropped dramatically, mirroring a spike in virtual visits. As lockdown is being lifted, in-person visits are seeing a gradual recovery, but still represent a fraction compared to pre-COVID levels.
- In-person visits have seen a rebound in mid-June, after a decrease of nearly 60% from February to mid-March but are still one-third lower than what they were before the pandemic.
- U.S. consumers using telemedicine passed from 11% in 2019 to 46% in May 2020.
Building Foundations For Long-term Growth
In the midst of a major change
The main barriers to telemedicine adoption include the regulatory & reimbursement hurdles, the lack of proper IT infrastructure, lack of awareness and concerns about reliability and effectiveness.
- Only 18% of physicians used telemedicine in 2018.
- Insurers paid roughly 20% to 50% less for virtual visits than in-patient visits.
New membership subscriptions are spiking
Telemedicine companies have seen a surge in both members and visits, particularly through March and April. The huge uptick in virtual visits could be extraordinary and tied to the emergency created by the virus. However, membership subscriptions usually are long-term contracts.
- During Q1, Teladoc, leading provider of telemedicine services, reported U.S. membership subscriptions up 61% YoY, while U.S. members with visit-feeonly access rose 89% YoY.
Permanent reimbursement expansion: the next catalyst
The healthcare industry has called on health officials to make permanent the favorable payment conditions set during the COVID-19 outbreak. Reimbursement expansion is necessary to incentivize providers to invest in telemedicine infrastructure and keep patients using it for low-acuity and emergency visits.
- CMS has already issued a proposed rule to make permanent some of the temporary provisions, starting January 1, 2021.
New Investment Opportunities On The Horizon
New companies are filing for an IPO
Telemedicine companies are seeing increased investors' interest. Teladoc has been so far the main listed pure player in the U.S. but more companies are going public.
- One Medical went public on January 31.
- Ping An Good Doctor was one of the biggest Hong Kong IPOs of 2018.
- Amwell is exploring an IPO, currently scheduled for September.
- Oak Street Health has just filed for a $100mn IPO.
Telemedicine was originally designed for emergency care
Most telemedicine players are not intended to replace the primary care physician. They are mainly focused on behavioral and emergency care, cannot order laboratory tests or dispense prescription drugs. Patients don’t receive ongoing care with the same person through the illness as a random doctor is assigned every time.
- Teladoc and Amwell offer a 10 minutes remote conversation with a random doctor, who cannot dispense prescription drugs or order tests to confirm a diagnosis.
New business models are emerging
Telemedicine has been focused on low-acuity urgent care but has still a lot of opportunities for expansion, such as follow-up for surgery and cancer therapy, although in-person visits will still be needed.
- Teladoc and Amwell provide virtual-first primary care but other companies, such as One Medical, are exploring a hybrid business model, that mixes telemedicine and office visits.

A Hybrid Business Model
Primary care is ripe for disruption
Primary care consumers are dissatisfied with their experience. Long waiting times for appointments, short visits, uninviting offices, as well as limited access to specialists have led to innovative primary care solutions.
- Physicians are paid on a fee-for-service basis, incentivizing them to enroll as many patients as possible to maximize their income.
- In 2019 Mayo Clinic reported that over 50% of primary care physicians showed burnout symptoms.
One Medical changes the way primary care is delivered
One Medical is a membership-based primary care provider. Through an app, members can text their physician, schedule same-day appointments in more than 70 locations around U.S., get video visits 24/7, renew prescriptions, and be treated in comfortable, uncrowded settings.
- The fee structure encourages patients to use their services leading to more preventative care.
A value-added service for both members and physicians
Electronic business model creates value for patients, physicians and employers. The company pays its doctors an annual salary, removing the incentives for clinical volume and improving the quality of care. Technology allows physicians to focus on meaningful work and increase productivity.
- Electronic health record (EHR) facilitates 44% of administrative tasks.
- One Medical has been shown to lower employer medical costs by 8% or more.
Catalysts
- Permanent reimbursement expansion. CMS issued a proposed rule to make permanent some of the temporary provisions set during the pandemic, starting January 1, 2021.
- Increased adoption. During the pandemic, physicians and patients have experienced firsthand the benefits of telemedicine, forcing them to test the technology and acknowledge its potential.
- Surge of IPOs. The increase in public companies will help boost visibility to consumers and partners.
Sources:
What are the technical infrastructure requirements of telehealth?
Telemedicine Technology
Technology Requirements in Telemedicine
Using Telehealth to Care for Patients During the COVID-19 Pandemic
Key changes made to telehealth guidelines to boost COVID-19 care
Secretary Azar Announces Historic Expansion of Telehealth Access to Combat COVID-19
Telehealth: A quarter-trillion-dollar post-COVID-19 reality?
CMS Proposes Calendar Year 2021 Payment and Policy Changes for Home Health Agencies and Calendar Year 2021 Home Infusion Therapy Benefit
Companies mentioned in this article:
Teladoc (TDOC US), Amwell (not listed), 1Life Healthcare (ONEM US), Oak Street Health (not listed), Ping An Good Doctor (1833 HK), Alphabet (GOOG US)
Risks
- Physicians’ capacity. Telemedicine providers may not have enough clinical staff to offer remote care.
- Infrastructure, resources and training. Switching to telemedicine requires both the appropriate IT infrastructure and expertise.
- 2020 elections. Several presidential candidates are pushing for a public insurance option. If people start to sign up with the government, some companies might stop offering health insurance to their employees.
Explore:
Disclaimer
This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.
As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.
The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.
Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.
It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.
Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.